|Bid||44.96 x 800|
|Ask||45.99 x 1100|
|Day's range||42.42 - 46.06|
|52-week range||17.43 - 55.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Earnings date||05 Aug 2020 - 10 Aug 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||53.00|
Considered one of the highest distinctions in science for researchers working in the Netherlands, a maximum of two Stevin Prizes are awarded by the Dutch Research Council (NWO) each year to a researcher or team whose work has a major social impact. “We are thrilled that Ton, an internationally renowned immunologist and researcher, has been recognized for his outstanding pioneering and inspiring contributions to cancer immunotherapy with the prestigious Stevin Prize,” said David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene.
Is (ALLO) Outperforming Other Medical Stocks This Year?
“Our goal is to remain at the forefront of innovation in allogeneic cell therapy, and these studies inform our ability to optimize AlloCAR T therapy for both hematologic and solid tumors,” said Barbra Sasu, Ph.D., Chief Scientific Officer of Allogene. “The findings from these two presentations provide strong scientific rationale for both our AlloCAR and TurboCAR technologies – two key components of our advancing AlloCAR T platform.” In research featured during the virtual meeting, genetically modified T cells expressing chimeric antigen receptors (CARs) targeting Delta-like ligand 3 (DLL3) were screened, characterized and ranked against targets using in vitro cytotoxicity assays.
FLT3-Directed AlloCAR T™ Therapy Demonstrated Potent Anti-Leukemic Activity in Pre-Clinical Models Without Evidence of Off-Target Activity SOUTH SAN FRANCISCO, Calif., June.
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SOUTH SAN FRANCISCO, Calif., June 03, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T.
The gross proceeds from this offering are expected to be approximately $550.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Allogene. In addition, Allogene has granted the underwriters a 30-day option to purchase up to 1,755,319 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. Goldman Sachs & Co. LLC, Jefferies LLC and Cowen and Company, LLC are acting as joint lead book-running managers for the offering.
Allogene Therapeutics, Inc. (ALLO), today announced the commencement of an underwritten public offering of $450.0 million of shares of its common stock. In addition, Allogene expects to grant the underwriters a 30-day option to purchase up to an additional $67.5 million of shares of its common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Allogene.
ALLO-501 with ALLO-647 Lymphodepletion was Well Tolerated with No Dose-Limiting Toxicities, Graft-vs-Host Disease or Immune Effector Cell-Associated Neurotoxicity Syndrome.
Allogene Therapeutics, Inc. (ALLO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Webinar Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., May 26, 2020 -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company.
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host DiseaseAbstract Based on.
Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology.
Allogene Therapeutics (ALLO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season